WO2005041924A3 - Administration of levodopa and carbidopa - Google Patents

Administration of levodopa and carbidopa Download PDF

Info

Publication number
WO2005041924A3
WO2005041924A3 PCT/US2004/036039 US2004036039W WO2005041924A3 WO 2005041924 A3 WO2005041924 A3 WO 2005041924A3 US 2004036039 W US2004036039 W US 2004036039W WO 2005041924 A3 WO2005041924 A3 WO 2005041924A3
Authority
WO
WIPO (PCT)
Prior art keywords
carbidopa
levodopa
administration
substances
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/036039
Other languages
French (fr)
Other versions
WO2005041924A2 (en
Inventor
Patrick S L Wong
Dong Yan
Stephen Hwang
George V Guittard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alza Corp
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Priority to JP2006538322A priority Critical patent/JP2007509972A/en
Priority to EP04810117A priority patent/EP1677756A2/en
Priority to AU2004285532A priority patent/AU2004285532A1/en
Priority to CA002543227A priority patent/CA2543227A1/en
Publication of WO2005041924A2 publication Critical patent/WO2005041924A2/en
Publication of WO2005041924A3 publication Critical patent/WO2005041924A3/en
Priority to IL175314A priority patent/IL175314A0/en
Anticipated expiration legal-status Critical
Priority to NO20062508A priority patent/NO20062508L/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed are substances, compositions, dosage forms and methods that comprise levodopa and/or carbidopa.
PCT/US2004/036039 2003-10-31 2004-10-29 Administration of levodopa and carbidopa Ceased WO2005041924A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2006538322A JP2007509972A (en) 2003-10-31 2004-10-29 Administration of levodopa and carbidopa
EP04810117A EP1677756A2 (en) 2003-10-31 2004-10-29 Administration of levodopa and carbidopa
AU2004285532A AU2004285532A1 (en) 2003-10-31 2004-10-29 Administration of levodopa and carbidopa
CA002543227A CA2543227A1 (en) 2003-10-31 2004-10-29 Administration of levodopa and carbidopa
IL175314A IL175314A0 (en) 2003-10-31 2006-04-27 Administration of levodopa and carbidopa
NO20062508A NO20062508L (en) 2003-10-31 2006-05-31 Administration of levodopa and carbidopa

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US51625903P 2003-10-31 2003-10-31
US60/516,259 2003-10-31
US51950903P 2003-11-12 2003-11-12
US60/519,509 2003-11-12

Publications (2)

Publication Number Publication Date
WO2005041924A2 WO2005041924A2 (en) 2005-05-12
WO2005041924A3 true WO2005041924A3 (en) 2005-11-10

Family

ID=34556123

Family Applications (6)

Application Number Title Priority Date Filing Date
PCT/US2004/036043 Ceased WO2005041928A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for ehnanced absorption of iron
PCT/US2004/036040 Ceased WO2005041925A2 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption
PCT/US2004/036039 Ceased WO2005041924A2 (en) 2003-10-31 2004-10-29 Administration of levodopa and carbidopa
PCT/US2004/036042 Ceased WO2005041927A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
PCT/US2004/036041 Ceased WO2005041926A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
PCT/US2004/036038 Ceased WO2005041923A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of metformin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2004/036043 Ceased WO2005041928A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for ehnanced absorption of iron
PCT/US2004/036040 Ceased WO2005041925A2 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption

Family Applications After (3)

Application Number Title Priority Date Filing Date
PCT/US2004/036042 Ceased WO2005041927A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
PCT/US2004/036041 Ceased WO2005041926A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid
PCT/US2004/036038 Ceased WO2005041923A1 (en) 2003-10-31 2004-10-29 Compositions and dosage forms for enhanced absorption of metformin

Country Status (14)

Country Link
US (6) US20050163848A1 (en)
EP (6) EP1677759A1 (en)
JP (6) JP2007509975A (en)
KR (6) KR20060108692A (en)
AU (4) AU2004285531A1 (en)
BR (1) BRPI0416138A (en)
CA (6) CA2543238A1 (en)
EC (1) ECSP066535A (en)
IL (4) IL175194A0 (en)
MA (1) MA28140A1 (en)
MX (1) MXPA06004960A (en)
NO (4) NO20062513L (en)
RU (1) RU2006118801A (en)
WO (6) WO2005041928A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
DE10249552A1 (en) 2002-10-23 2004-05-13 Vifor (International) Ag Water-soluble iron-carbohydrate complexes, their preparation and medicaments containing them
EP1677759A1 (en) * 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin
CA2574977C (en) * 2004-07-29 2010-01-26 X-Sten, Corp. Spinal ligament modification devices
US20060189635A1 (en) * 2005-02-04 2006-08-24 Michelle Kramer Enhanced efficacy benzisoxazole derivative dosage forms and methods
PE20061245A1 (en) * 2005-03-30 2007-01-06 Generex Pharm Inc COMPOSITIONS FOR ORAL TRANSMUCOUS TRANSMISSION OF METFORMIN
KR20080005429A (en) * 2005-04-19 2008-01-11 알자 코포레이션 Combinations of Materials Containing Tramadol and Gabapentin
AU2006239929B2 (en) 2005-04-22 2011-11-03 Alantos Pharmaceuticals Holding, Inc. Dipeptidyl peptidase-IV inhibitors
AU2006261893A1 (en) * 2005-06-23 2007-01-04 Combinatorx, Incorporated Improved dosage forms for movement disorder treatment
JP2009502365A (en) * 2005-07-29 2009-01-29 ヴァートス メディカル インコーポレーテッド Percutaneous tissue resection device and method
NL2000281C2 (en) 2005-11-02 2007-08-07 Pfizer Prod Inc Solid pharmaceutical compositions containing pregabalin.
US20070123890A1 (en) * 2005-11-04 2007-05-31 X-Sten, Corp. Tissue retrieval devices and methods
CN101365432B (en) * 2005-12-16 2011-06-22 默沙东公司 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
EP1973549B1 (en) 2006-01-06 2016-07-20 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron
KR101191322B1 (en) * 2006-04-07 2012-10-16 메리온 리서치 Ⅲ 리미티드 Solid oral dosage form containing an enhancer
US7942830B2 (en) 2006-05-09 2011-05-17 Vertos Medical, Inc. Ipsilateral approach to minimally invasive ligament decompression procedure
USD606654S1 (en) 2006-07-31 2009-12-22 Vertos Medical, Inc. Tissue excision device
USD620593S1 (en) 2006-07-31 2010-07-27 Vertos Medical, Inc. Tissue excision device
WO2008052044A2 (en) * 2006-10-26 2008-05-02 Xenoport, Inc. Use of derivatives of propofol for treating diseases associated with oxidative stress
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
US8637080B2 (en) * 2007-06-28 2014-01-28 Osmotica Kereskedelmi és Szolgáltató, KFT Rupturing controlled release device comprising a subcoat
WO2009080365A1 (en) * 2007-12-21 2009-07-02 Synthon B.V. Pregabalin salts
CN107096012A (en) * 2008-05-07 2017-08-29 诺和诺德股份有限公司 Composition of peptide and preparation method thereof
CN102159539B (en) 2008-06-26 2014-04-16 矽烷实验室股份公司 A new metformin glycinate salt for blood glucose control
JP2012500221A (en) * 2008-08-15 2012-01-05 ディポメド，インコーポレイティド Gastric retentive pharmaceutical composition for treatment and prevention of CNS disorders
EP2343973B1 (en) * 2008-09-12 2016-02-17 Cadila Pharmaceuticals Ltd. Prodrugs of Sitagliptin
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
WO2010134074A1 (en) * 2009-05-19 2010-11-25 Neuroderm Ltd Compositions for continuous administration of dopa decarboxylase inhibitors
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011120033A1 (en) * 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
CN103025327A (en) * 2010-06-09 2013-04-03 艾米斯菲尔技术公司 Oral iron deficiency therapy
CA2802335A1 (en) * 2010-06-22 2011-12-29 Twi Pharmaceuticals, Inc. Controlled release compositions with reduced food effect
US20130251795A1 (en) * 2010-07-30 2013-09-26 Ranbaxy Laboratories Limited Pharmaceutical compositions containing a biguanide and a low dose antidiabetic agent
WO2012061165A2 (en) * 2010-10-25 2012-05-10 Lu Xiandan Sharon Methods and compositions for improving admet properties
EP2635272A1 (en) 2010-11-01 2013-09-11 Intec Pharma Ltd. Accordion pill comprising levodopa for an improved treatment of parkinson's disease symptoms
EP2640358B1 (en) 2010-11-15 2018-01-03 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US8796338B2 (en) 2011-01-07 2014-08-05 Elcelyx Therapeutics, Inc Biguanide compositions and methods of treating metabolic disorders
US9572784B2 (en) 2011-01-07 2017-02-21 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
HUE051738T2 (en) 2011-01-07 2021-03-29 Anji Pharma Us Llc Chemosensory receptor ligand-based therapies
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US9480663B2 (en) 2011-01-07 2016-11-01 Elcelyx Therapeutics, Inc. Biguanide compositions and methods of treating metabolic disorders
EP2661273A4 (en) * 2011-01-07 2014-06-04 Merrion Res Iii Ltd Pharmaceutical compositions of iron for oral administration
US11974971B2 (en) 2011-01-07 2024-05-07 Anji Pharmaceuticals Inc. Compositions and methods for treating metabolic disorders
US11759441B2 (en) 2011-01-07 2023-09-19 Anji Pharmaceuticals Inc. Biguanide compositions and methods of treating metabolic disorders
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
EP2527319A1 (en) 2011-05-24 2012-11-28 Laboratorios Del. Dr. Esteve, S.A. Crystalline forms of pregabalin and co-formers in the treatment of pain
EA033067B1 (en) 2012-01-06 2019-08-30 Элселикс Терапьютикс, Инк. Method for treating metabolic disorders in a patient having a contraindication for a biguanide compound
KR20200137035A (en) 2012-01-06 2020-12-08 앤지 파마 유에스 엘엘씨 Biguanide compositions and methods of treating metabolic disorders
PL2854764T3 (en) 2012-06-05 2019-07-31 Neuroderm Ltd Compositions comprising apomorphine and organic acids and uses thereof
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
BR112015005878A2 (en) * 2012-09-17 2017-07-04 Bind Therapeutics Inc therapeutic nanoparticles comprising therapeutic agent and methods of preparing and using them
US20140100282A1 (en) * 2012-10-10 2014-04-10 Patrick S L Wong Intranasal administration of pharmaceutical agents for treatment of neurological diseases
ES2540581T3 (en) 2012-10-17 2015-07-10 Methylation Sciences International Srl Compositions comprising S-adenosylmethionine and a gallic acid ester
CN104412970B (en) * 2013-09-10 2017-01-11 贵州大自然科技股份有限公司 Natural latex vessel disinfectant and using method thereof
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2967693T3 (en) 2014-03-13 2024-05-03 Neuroderm Ltd Dopa decarboxylase inhibitor compositions
ES2546897B2 (en) * 2014-03-27 2016-02-01 Universidad De Sevilla Use of metformin and derivatives with activity as inducers of AMPK phosphorylation for the treatment of fibromyalgia
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
CA2951923A1 (en) 2014-06-18 2015-12-23 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of active agents
RU2743347C2 (en) 2014-10-21 2021-02-17 Эббви Инк. Carbidopa and l-dopa prodrugs and use thereof for treating parkinson's disease
WO2016112381A1 (en) 2015-01-09 2016-07-14 The Board Of Trustees Of The University Of Illinois Restoring physiology in iron-deficient organisms using small molecules
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
AU2016258179B2 (en) * 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
EP3445346A1 (en) * 2016-04-20 2019-02-27 AbbVie Inc. Carbidopa and l-dopa prodrugs and methods of use
ES2827796T3 (en) 2016-06-03 2021-05-24 Thetis Pharmaceuticals Llc Compositions and procedures related to salts of specialized pro-resolution mediators of inflammation
CA3030105A1 (en) 2016-07-17 2018-01-25 Mapi Pharma Ltd. Extended release dosage forms of pregabalin
WO2018049078A1 (en) 2016-09-07 2018-03-15 Vertos Medical, Inc. Percutaneous lateral recess resection methods and instruments
BR112019006401A2 (en) 2016-09-30 2019-06-25 Laboratorios Silanes S A De C V metformin glycinate, pharmaceutical compositions comprising the same and methods of use thereof
WO2018060962A2 (en) 2016-09-30 2018-04-05 Laboratorios Silanes S.A. De C.V. Metformin amino acid compounds and methods of using the same
CN113292537B (en) * 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 Salts of kinase inhibitors and compositions thereof
KR102917176B1 (en) 2018-09-05 2026-01-27 레노파마 아베 Iron-containing composition and its use
CN113015531A (en) 2018-11-15 2021-06-22 艾伯维公司 Pharmaceutical formulation for subcutaneous administration
CN114615972A (en) * 2019-06-21 2022-06-10 卡希夫生物科学有限公司 Gastroretentive dosage forms of levodopa and carbidopa
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2022119430A1 (en) 2020-12-04 2022-06-09 Laboratorios Silanes S.A. De C.V. Stable coated solid pharmaceutical composition of an opioid analgesic and an anti-epileptic for pain
PE20241278A1 (en) * 2021-06-16 2024-06-21 The Texas Aandm Univ System EDIBLE NANOCOATINGS AND METHODS OF USING THEM
WO2023245144A1 (en) 2022-06-16 2023-12-21 Vertos Medical, Inc. Integrated instrument assembly
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease
AU2024274445A1 (en) 2023-05-15 2025-11-27 Bonafide Health, Llc Sleep-improving compositions and methods of use

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916004A (en) * 1972-12-02 1975-10-28 Sankyo Co Process for producing dopa preparation
US4729989A (en) * 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa
WO2003005967A2 (en) * 2001-07-12 2003-01-23 Teva Pharmaceutical Industries, Ltd. Dual release levodopa ethyl ester and decarboxylase in controlled release core
WO2003041646A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003053400A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3995631A (en) * 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
JPS5421404B2 (en) * 1972-02-23 1979-07-30
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
FR2243684B1 (en) * 1973-09-19 1977-01-28 Semb
US4077407A (en) * 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) * 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4432987A (en) * 1982-04-23 1984-02-21 Pfizer Inc. Crystalline benzenesulfonate salts of sultamicillin
US4432967A (en) * 1982-06-25 1984-02-21 National Starch And Chemical Corp. Contraceptive composition
US4519801A (en) * 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4681583A (en) * 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US4578075A (en) * 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
BE896423A (en) * 1983-04-11 1983-08-01 Ct Europ De Rech S Therapeutiq Doxycycline aliphatic sulphate(s), esp. lauryl-sulphate - antibiotics having superior lipo-solubility, leading to improved blood levels and antimicrobial activity
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US5082668A (en) * 1983-05-11 1992-01-21 Alza Corporation Controlled-release system with constant pushing source
DK149776C (en) * 1984-01-06 1987-04-21 Orion Yhtymae Oy ANTIBIOTIC EFFECT OF ERYTHROMYCIN COMPOUND AND PREPARATION CONTAINING THE COMPOUND
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins
JPS62120339A (en) * 1985-11-20 1987-06-01 Mitsui Petrochem Ind Ltd Production of ferric salt of long-chain fatty acid
US4971790A (en) * 1986-02-07 1990-11-20 Alza Corporation Dosage form for lessening irritation of mocusa
US5236689A (en) * 1987-06-25 1993-08-17 Alza Corporation Multi-unit delivery system
US5190933A (en) * 1987-12-04 1993-03-02 Ciba-Geigy Corporation Substituted propane-phosphinic acid compounds
US5300679A (en) * 1987-12-04 1994-04-05 Ciba-Geigy Corporation Substituted propane-phosphinic acid compounds
GB8728483D0 (en) * 1987-12-04 1988-01-13 Ciba Geigy Ag Chemical compounds
GB2212396A (en) * 1987-12-18 1989-07-26 Procter & Gamble Dietary supplement comprising calcium and delayed release coated iron
US5019397A (en) * 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5007790A (en) * 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5091190A (en) * 1989-09-05 1992-02-25 Alza Corporation Delivery system for administration blood-glucose lowering drug
US5024843A (en) * 1989-09-05 1991-06-18 Alza Corporation Oral hypoglycemic glipizide granulation
US5158850A (en) * 1989-12-15 1992-10-27 Ricoh Company, Ltd. Polyether compounds and electrophotographic photoconductor comprising one polyether compound
IL114631A (en) * 1990-06-22 1998-12-06 Novartis Ag Anti-epileptic compositions containing gabab- antagonistic compounds
US5156850A (en) * 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US5858407A (en) * 1992-02-27 1999-01-12 Alza Corporation Method for administering tandospirone
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
JP3301177B2 (en) * 1993-09-03 2002-07-15 王子製紙株式会社 Thermal recording medium
US5536507A (en) * 1994-06-24 1996-07-16 Bristol-Myers Squibb Company Colonic drug delivery system
US5534263A (en) * 1995-02-24 1996-07-09 Alza Corporation Active agent dosage form comprising a matrix and at least two insoluble bands
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
DE19616486C5 (en) * 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Method for lowering the blood glucose level in mammals
US6255502B1 (en) * 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
DE19645043A1 (en) * 1996-10-31 1998-05-07 Inst Neue Mat Gemein Gmbh Process for the production of substrates with high-temperature and UV-stable, transparent, colored coatings
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
RU2161963C2 (en) * 1997-05-19 2001-01-20 Российский научно-исследовательский институт гематологии и трансфузиологии Trivalent iron fumarate hydrate as agent for treating iron-deficient anemia pharmaceutical composition based on said agent
EP1009452A4 (en) * 1997-08-07 2004-03-31 Ajay Gupta Dialysis solutions containing water soluble vitamins and nutrients
PT1003476E (en) * 1997-08-11 2005-05-31 Alza Corp ACTIVE AGGREGATE AGGREGATE DOSAGE FORM ADAPTED FOR GASTRIC RETENTION
JP4095772B2 (en) * 1997-11-18 2008-06-04 財団法人微生物化学研究会 Novel bioactive substance sulfostine, its production method and its use
ATE261935T1 (en) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co NEW METFORMIN SALTS AND METHODS
EP1043031A4 (en) * 1997-12-26 2007-05-02 Astellas Pharma Inc Sustained release medicinal compositions
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
DE19828113A1 (en) * 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19828114A1 (en) * 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
HUP0104993A3 (en) * 1998-11-02 2003-02-28 Alza Corp Mountain View Method and device for controlled delivery of active agents
US6107317A (en) * 1999-06-24 2000-08-22 Novartis Ag N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
FR2796940B1 (en) * 1999-07-26 2005-04-08 Lipha NOVEL METFORMIN SALTS, PROCESS FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
JP3485060B2 (en) * 2000-03-08 2004-01-13 日本電気株式会社 Information processing terminal device and mobile phone terminal connection method used therefor
CN1141974C (en) * 2000-06-07 2004-03-17 张昊 Colon-releasing oral biological preparation
DE60101476T2 (en) * 2000-06-16 2004-05-27 Teva Pharmaceutical Industries Ltd. STABLE GABAPENTIN CONTAINING MORE THAN 20 PPM CHLORINE
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
US7085708B2 (en) * 2000-09-23 2006-08-01 Ravenflow, Inc. Computer system with natural language to machine language translator
US6451808B1 (en) * 2000-10-17 2002-09-17 Depomed, Inc. Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists
US7273623B2 (en) * 2001-10-12 2007-09-25 Kiel Laboratories, Inc. Process for preparing tannate tablet, capsule or other solid dosage forms
US6890918B2 (en) * 2001-04-30 2005-05-10 Shire Laboratories, Inc. Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers
US7420002B2 (en) * 2001-06-11 2008-09-02 Xenoport Amino acid conjugates providing for sustained systemic concentrations of GABA analogues
ITMI20011337A1 (en) * 2001-06-26 2002-12-26 Farmatron Ltd ORAL PHARMACEUTICAL COMPOSITIONS WITH MODIFIED RELEASE OF THE ACTIVE SUBSTANCE
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030158254A1 (en) * 2002-01-24 2003-08-21 Xenoport, Inc. Engineering absorption of therapeutic compounds via colonic transporters
AU2003211131A1 (en) * 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
WO2004093866A1 (en) * 2003-03-25 2004-11-04 Kiel Laboratories, Inc. Process for preparing phenolic acid salts of gabapentin
WO2004091278A2 (en) * 2003-04-11 2004-10-28 Transform Pharmaceuticals, Inc. Gabapentin compositions
US7611728B2 (en) * 2003-09-05 2009-11-03 Supernus Pharmaceuticals, Inc. Osmotic delivery of therapeutic compounds by solubility enhancement
EP1677759A1 (en) * 2003-10-31 2006-07-12 Alza Corporation Compositions and dosage forms for enhanced absorption of gabapentin and pregabalin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3916004A (en) * 1972-12-02 1975-10-28 Sankyo Co Process for producing dopa preparation
US4729989A (en) * 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
EP0260236A1 (en) * 1986-08-26 1988-03-16 ASTA Pharma Aktiengesellschaft Composition comprising L-dopa
WO2003005967A2 (en) * 2001-07-12 2003-01-23 Teva Pharmaceutical Industries, Ltd. Dual release levodopa ethyl ester and decarboxylase in controlled release core
WO2003041646A2 (en) * 2001-11-13 2003-05-22 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
WO2003053400A1 (en) * 2001-12-19 2003-07-03 Alza Corporation Formulation & dosage form for the controlled delivery of therapeutic agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMPBELL R R A ET AL: "THE EFFECT OF FERROUS SULFATE AND PH ON L DOPA ABSORPTION", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, vol. 68, no. 5, 1990, pages 603 - 607, XP009045786, ISSN: 0008-4212 *
SASAHARA K ET AL: "DOSAGE FORM DESIGN FOR IMPROVEMENT OF BIO AVAILABILITY OF L DOPA 5. ABSORPTION AND METABOLISM OF L DOPA IN INTESTINAL SEGMENTS OF DOGS", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 70, no. 10, 1981, pages 1157 - 1160, XP009045807, ISSN: 0022-3549 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9393192B2 (en) 2002-07-29 2016-07-19 Alza Corporation Methods and dosage forms for controlled delivery of paliperidone and risperidone

Also Published As

Publication number Publication date
EP1677756A2 (en) 2006-07-12
JP2007509975A (en) 2007-04-19
WO2005041925A2 (en) 2005-05-12
JP2007509972A (en) 2007-04-19
WO2005041927A1 (en) 2005-05-12
KR20060109922A (en) 2006-10-23
JP2007509976A (en) 2007-04-19
US20050163841A1 (en) 2005-07-28
KR20060130571A (en) 2006-12-19
JP2007509974A (en) 2007-04-19
CA2543185A1 (en) 2005-05-12
US20050163850A1 (en) 2005-07-28
EP1677759A1 (en) 2006-07-12
JP2007509971A (en) 2007-04-19
KR20060108692A (en) 2006-10-18
IL175305A0 (en) 2006-09-05
IL175306A0 (en) 2006-09-05
US20050163849A1 (en) 2005-07-28
NO20062508L (en) 2006-07-31
CA2543945A1 (en) 2005-05-12
KR20060103440A (en) 2006-09-29
JP2007509973A (en) 2007-04-19
KR20060123219A (en) 2006-12-01
AU2004285535A1 (en) 2005-05-12
WO2005041928A1 (en) 2005-05-12
WO2005041925A3 (en) 2005-09-29
CA2543238A1 (en) 2005-05-12
EP1677757A2 (en) 2006-07-12
EP1680082A1 (en) 2006-07-19
AU2004285531A1 (en) 2005-05-12
IL175314A0 (en) 2006-09-05
US20060094782A9 (en) 2006-05-04
AU2004285533A1 (en) 2005-05-12
ECSP066535A (en) 2006-10-10
WO2005041926A1 (en) 2005-05-12
EP1680083A1 (en) 2006-07-19
US20050158374A1 (en) 2005-07-21
AU2004285532A1 (en) 2005-05-12
CA2543177A1 (en) 2005-05-12
IL175194A0 (en) 2006-09-05
WO2005041924A2 (en) 2005-05-12
RU2006118801A (en) 2007-12-10
BRPI0416138A (en) 2007-01-02
WO2005041923A1 (en) 2005-05-12
NO20062513L (en) 2006-07-27
NO20062504L (en) 2006-07-21
US20050163848A1 (en) 2005-07-28
CA2543227A1 (en) 2005-05-12
MXPA06004960A (en) 2007-01-19
US20050165102A1 (en) 2005-07-28
EP1677758A1 (en) 2006-07-12
NO20062512L (en) 2006-07-31
CA2543181A1 (en) 2005-05-12
MA28140A1 (en) 2006-09-01
KR20060109923A (en) 2006-10-23

Similar Documents

Publication Publication Date Title
WO2005041924A3 (en) Administration of levodopa and carbidopa
WO2005023185A3 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003303458A1 (en) Ampholytic copolymer and use thereof
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
AU2003297684A1 (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
WO2006131591A3 (en) An entacapone-containing oral dosage form
PL1654253T3 (en) Substituted 3-pyrrolidin-indole derivatives
NO20055130L (en) Aminocyclohexyl ether compounds and their use
AU2003293555A1 (en) 17 beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
MY135829A (en) Analeptic and drug combinations
IL174479A (en) Hemiasterlin derivatives, pharmaceutical compositions comprising the same and uses thereof
WO2006113568A8 (en) Controlled delivery dosage form of tramadol and gabapentin
MY130792A (en) 17ß-HYDROXYSTEROID DEHYDROGENASE TYPE 3 INHIBITORS FOR THE TREATMENT OF ANDROGEN DEPENDENT DISEASES
WO2004073615A3 (en) Deazaflavin compounds and methods of use thereof
NO20062605L (en) Pharmaceutical formulation containing flavoring substances with improved pharmaceutical properties
AU2003218359A1 (en) Polymer composition and dosage forms comprising the same
PL374761A1 (en) N-benzodioxolyl, n-benzodioxanyl and n-benzodioxepinyl arylcarbonxamide derivatives, and pharmaceutical compositions comprising them
WO2004073686A3 (en) Menthol solutions of drugs
WO2004019965A3 (en) Thymus-based tolerogenic approaches for type i diabetes.
WO2005094761A8 (en) Hair treatment compositions comprising a disaccharide, a di-acid and a source of ammonium ions
AU2003234084A1 (en) Creatine salt having enhanced nutritional, antioxidant and therapeutic efficacy and compositions containing same
NO20054346L (en) Compositions and methods for the prevention and treatment of endotoxin-related diseases and conditions
WO2006044548A3 (en) Clopidogrel compositions
AU2003227361A1 (en) DECOY FOR TREATING AND/OR PREVENTING Th2 CYTOKINE-ASSOCIATED ALLERGIC DISEASE, GATA3 MUTANT PROTEIN AND MEDICINAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200480039272.7

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2543227

Country of ref document: CA

Ref document number: 546701

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004285532

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 175314

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2006538322

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004810117

Country of ref document: EP

Ref document number: PA/a/2006/004962

Country of ref document: MX

Ref document number: 1134/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004285532

Country of ref document: AU

Date of ref document: 20041029

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285532

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2006/04424

Country of ref document: ZA

Ref document number: 200604424

Country of ref document: ZA

Ref document number: 1020067010558

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2004810117

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010558

Country of ref document: KR